ReviewFrontiers in cell and developmental biology2025
Mesenchymal stromal/stem cell-derived exosomes as a potential therapeutic approach to osteoarthritis combined with type 2 diabetes mellitus.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Metabolic disorders and osteoarthritis: novel insights into pathological mechanisms and therapeutic strategies.Life medicine · 2026Review
- Molecular mechanisms governing exosome biogenesis, engineering strategies, and emerging role as cell-free therapeutics.Molecular biology reports · 2026Review
- Regenerative and Stem Cell-Based Therapies for Arthritis: Harnessing Mesenchymal Stem Cells, Exosomes, and Bioengineered Scaffolds for Functional Joint Repair.Stem cell reviews and reports · 2026Review
- Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis.Stem cells international · 2026Review
- Integrated metabolomics and computational analysis suggest that aFrontiers in nutrition · 2026Article
- Exo-hydrogel therapy: a revolutionary approach to managing diabetic complications.Journal of nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) and type 2 diabetes mellitus (T2DM) often coexist due to shared risk factors and high prevalence, but effective treatment methods are currently lacking. Mesenchymal stromal/stem cell-derived exosomes (MSC-Exos) have regenerative properties that can repair cartilage damage, lower blood sugar levels, and improve pancreatic β cell function, showing great potential in tissue repair. This review primarily explores the application of MSC-Exos in the treatment of OA and T2DM, the potential mechanisms of MSC-Exos, and the therapeutic strategies of engineered exosomes. Although MSC-Exo therapy shows promising therapeutic potential, further research is needed to validate its safety and feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.